RBM5 and acute myeloid leukemia: The top two enriched GSEA pathways in the decreased genes after RBM5 KO are associated with FLT3 inhibitors, including gilteritinib and TP0903 (Fig. 5d), suggesting that the FLT3 gene might contribute to AML survival after the loss of RBM5.